Cardiologyprecision medicineLong QT syndrome
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
By MedXY|Sep 28, 2026
A phase 2 clinical study demonstrates that lumacaftor safely shortens QTc in LQT2 patients with KCNH2 trafficking defects, supported by patient-specific cardiomyocyte models validating the mechanism.